Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adhesion of TK-254RX in Healthy Volunteers
NCT06042192Phase 1Completed
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of esflurbiprofen in acute pain, contusion and soft tissue injury (2 arms), sponsored by Teikoku Seiyaku Co., Ltd. Primary endpoint: Characterization of adhesion 5 minutes prior to removal by the adhesion assessment by site staff with EFTS marked by site staff. Started Sep 2023; status: completed.
02
Drugs
esflurbiprofen
03
Conditions
acute paincontusionsoft tissue injury
Beyond the preview
Go deeper on NCT06042192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042192.